Thursday, November 26, 2020
Home Life Style Health & Fitness WHO Announces Global Trial To Look At 4 Most Promising Drugs For...

WHO Announces Global Trial To Look At 4 Most Promising Drugs For Treating Novel Coronavirus

The available data are thin and results from COVID-19 patients are murky

At a time when nearly 70 drugs and experimental cocktails are being examined to treat the novel coronavirus (COVID-19), the World Health Organisation (WHO) has announced a global trial called ‘SOLIDARITY to find out if any drug can actually treat infections with the new coronavirus.

The trial, which could include many thousands of patients in dozens of countries, has been designed to be as simple as possible so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate, according to the prestigious journal Science.

Scientists have suggested dozens of existing compounds for testing but WHO is focusing on what it says are the four most promising therapies. These are “an experimental antiviral compound called remdesivir; the malaria medications chloroquine and hydroxychloroquine; a combination of two HIV drugs, lopinavir and ritonavir; and that same combination plus interferon-beta, an immune system messenger that can help cripple viruses,” said the article in the journal of the American Association for the Advancement of Science (AAAS).

Originally developed by Gilead to combat Ebola and related viruses, remdesivir shuts down viral replication by inhibiting a key viral enzyme, the RNA-dependent RNA polymerase. The first COVID-19 patient diagnosed in the US — a young man in Snohomish County, Washington state — was given remdesivir when his condition worsened and he improved the next day, according to a case report in the New England Journal of Medicine (NEJM).

A Californian patient who received remdesivir recovered as well. When it comes to Chloroquine and hydroxychloroquine, the “WHO scientific panel designing SOLIDARITY had originally decided to leave the duo out of the trial but had a change of heart at a meeting in Geneva on 13 March, because the drugs “received significant attention” in many countries.”

The available data are thin and results from COVID-19 patients are murky. Chinese researchers who report treating more than 100 patients with chloroquine touted its benefits in a letter in BioScience, but the data underlying the claim have not been published. All in all, more than 20 COVID-19 studies in China used chloroquine or hydroxychloroquine, WHO notes, but their results have been hard to come by.

“WHO is engaging with Chinese colleagues at the mission in Geneva and have received assurances of improved collaboration; however, no data has been shared regarding the chloroquine studies.” Researchers in France have published a study in which they treated 20 COVID-19 patients with hydroxychloroquine. They concluded that the drug significantly reduced viral load in nasal swabs. But it was not a randomized controlled trial and it didn’t report clinical outcomes such as deaths.

“Hydroxychloroquine in particular might do more harm than good. The drug has a variety of side effects and can in rare cases harm the heart,” said the Science article. Ritonavir/lopinavir combination drug, sold under the brand name Kaletra, was approved in the US in 2000 to treat HIV infections.

Coronavirus
At a time when nearly 70 drugs and experimental cocktails are being examined to treat the novel coronavirus (COVID-19), the World Health Organisation (WHO) has announced a global trial called ‘SOLIDARITY to find out if any drug can actually treat infections with the new coronavirus. Pixabay

The first trial with COVD-19 was not encouraging, however. Doctors in Wuhan, China, gave 199 patients two pills of lopinavir/ritonavir twice a day plus standard care, or standard care alone.

There was no significant difference between the groups, they reported in the New England Journal of Medicine (NEJM) on March 15. “But the authors caution that patients were very ill — more than a fifth of them died — and so the treatment may have been given too late to help.”

ALSO READ: Every Second Car to Be Electric by 2050: Experts

Ritonavir/lopinavir+interferon beta is an another option. A combination of the three drugs is now being tested in MERS patients in Saudi-Arabia in the first randomized controlled trial for that disease. (IANS)

STAY CONNECTED

19,120FansLike
362FollowersFollow
1,780FollowersFollow

Most Popular

Identifying Mosquitoes Through App By Buzzing Sound

The high-pitched whine of a mosquito is annoying, but scientists have developed an app that uses that sound to detect dangerous mosquitoes. Mosquitoes kill hundreds...

Solomon Islands To Ban Facebook For National Unity

The government of the Solomon Islands has defended its plans to ban Facebook, insisting the move would preserve “national unity.” Ministers say the world's...

Gut Hormone Regulating Fat is Abnormal in Obesity

One key gut hormone released a few hours after eating, turns off fat production by regulating gene expression in the liver and this regulation...

50% Male Employees Agree Bias Against Women in Workplace

More than 50 percent of the men feel that there is an increased bias against women at the workplace, said a new survey. According to...

Here Are 10 Ways To Improve Self-Awareness Levels

Emotional intelligence tends to fuel one's performance on the personal front as well as professionally. Right from your self-assurance, empathy, and positivity to your...

Cooking With Biomass Fuels Damages Lungs

People who cook with biomass fuels like wood are at risk of suffering considerable damage to their lungs from breathing in dangerous concentrations of...

Pregnancy Stress Affects Infant’s Brain Development

Researchers have revealed that infants' brains may be shaped by levels of stress their mothers experience during pregnancy. The study, published in the journal eLife,...

What Does The Future Hold For Online Entertainment?

It’s hard to say exactly what kind of the year 2020 has been for the entertainment industry. While cinemas and theatres across the western world...

Recent Comments